Acknowledgment and Consent for Disclosure of an 18 U.S.C. §208 Particular Matter Waiver

SGE: Clyde W. Yancy, M.D.

Committee: Circulatory System Devices Panel of FDA's Medical Devices Advisory Committee

Meeting Date(s): October 10, 2007

I acknowledge that contingent upon public disclosure of the following financial interests submitted on my FDA Form 3410 and related to the agenda item: a premarket approval application, sponsored by Medtronic, Inc., for the Endeavor Zotarolimus-Eluting Coronary Stent System, which is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of length ≤ 27 mm in native coronary arteries with reference vessel diameters of ≥ 2.5mm to ≤ 3.5mm, I am eligible to receive a particular matter waiver under 18 U.S.C. §208.

Type of Interest	**Involvement**	**Magnitude**
Employer's Grant	SGE's institution involved in sponsor's product study; SGE is not involved in data generation or analysis	between $100,001 and $300,000
Consulting	parent of PMA sponsor	less than $10,001
Consulting	an unaffected unit of the parent of competing firms	less than $10,001

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of the interest, the waiver is not valid.

/S/ 09/19/07

Signature Date